Intangible Assets (Details Narrative) (10-K) - USD ($) |
3 Months Ended | 9 Months Ended | 12 Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 19, 2018 |
Oct. 04, 2017 |
Oct. 04, 2017 |
Sep. 30, 2019 |
Sep. 30, 2018 |
Jun. 30, 2018 |
Mar. 31, 2018 |
Sep. 30, 2019 |
Sep. 30, 2018 |
Dec. 31, 2018 |
Dec. 31, 2017 |
|
| Purchase of software license | $ (1,782) | $ (20,500) | |||||||||
| Capitalized cost, intangible asset | $ 3,037,147 | 3,037,147 | 11,038,929 | ||||||||
| Purchase price, intangible asset | 8,000,000 | ||||||||||
| Transaction costs, intangible asset | 1,782 | 1,782 | 1,782 | ||||||||
| Tax basis of intangible asset | $ 1,782 | $ 1,782 | $ 1,782 | ||||||||
| Number of shares provided in exchange for net assets | 31,745,242 | 2,090,301 | 2,090,301 | 2,090,301 | |||||||
| Common stock shares issued | 35,272,626 | 38,404,530 | 38,404,530 | 38,674,265 | 35,272,626 | ||||||
| Common stock shares outstanding | 35,272,626 | 38,404,530 | 38,404,530 | 38,674,265 | 35,272,626 | ||||||
| License agreement description | The negotiation of the modification to the Agreement was in process as of October 4, 2017 and was finalized in mid-February 2018 and the legal documents were thereafter executed and the option was exercised on March 19, 2018 in exchange for CoNCERT receiving: (i) $8 million of our common stock that was held by Promet LLC for the benefit of CoNCERT; (ii) royalties, on a product-by-product basis, on worldwide net sales of products during each year as follows: (a) four percent (4%) of sales less than or equal to $100 million; (b) five percent (5%) of sales greater than $100 million and less than or equal to $500 million; (c) six percent (6%) of sales greater than $500 million and less than or equal to $1 billion; and, (d) for that portion greater than $1 billion, (i) with respect to net sales made by Promet or any of its affiliates, ten percent (10%) of net sales, and (ii) with respect to net sales made by any sub-licensee, the greater of (1) 6% of such net sales or (2) 50% of all payments received by Promet or any of its affiliates with respect to such net sales; and (iii) 15% of any sublicense revenue earned by us for a period equivalent to the royalty term (as defined in the Agreement) until the earliest of (a) our raising $8 million of gross proceeds | ||||||||||
| Proceeds from common stock | $ 2,965,095 | $ 2,874,687 | |||||||||
| Amortization expense | $ 198,832 | $ 200,256 | 596,496 | $ 422,814 | $ 621,647 | ||||||
| Weighted average amortization period for intangible asset | 2 years | ||||||||||
| Future amortization expense, year two | 795,000 | 795,000 | $ 795,000 | ||||||||
| Future amortization expense, thereafter | $ 788,000 | $ 788,000 | $ 788,000 | ||||||||
| Agreement [Member] | |||||||||||
| Sub-licence agreement percentage | 15.00% | 15.00% | |||||||||
| Category 1 [Member] | Sub-licensee [Member] | |||||||||||
| Percentage of sales percentage | 6.00% | 6.00% | |||||||||
| CoNCERT Pharmaceuticals, Inc [Member] | |||||||||||
| Number of shares provided in exchange for net assets | 2,090,301 | ||||||||||
| Shares acquired price per share | $ 3.83 | ||||||||||
| Acquisition percentage | 6.00% | ||||||||||
| Percentage of controlling interest | 6.00% | ||||||||||
| Fair value of intangible assets | $ 8,000,000 | ||||||||||
| Proceeds from royalty receivable | $ 8,000,000 | ||||||||||
| Proceeds from common stock | $ 8,000,000 | ||||||||||
| CoNCERT Pharmaceuticals, Inc [Member] | Category 1 [Member] | |||||||||||
| Percentage of sales percentage | 4.00% | 4.00% | |||||||||
| CoNCERT Pharmaceuticals, Inc [Member] | Category 1 [Member] | Maximum [Member] | |||||||||||
| Amount of sales limit | $ 100,000,000 | ||||||||||
| CoNCERT Pharmaceuticals, Inc [Member] | Category 2 [Member] | |||||||||||
| Percentage of sales percentage | 5.00% | 5.00% | |||||||||
| CoNCERT Pharmaceuticals, Inc [Member] | Category 2 [Member] | Maximum [Member] | |||||||||||
| Amount of sales limit | $ 500,000,000 | ||||||||||
| CoNCERT Pharmaceuticals, Inc [Member] | Category 2 [Member] | Minimum [Member] | |||||||||||
| Amount of sales limit | $ 100,000,000 | ||||||||||
| CoNCERT Pharmaceuticals, Inc [Member] | Category 3 [Member] | |||||||||||
| Percentage of sales percentage | 6.00% | 6.00% | |||||||||
| CoNCERT Pharmaceuticals, Inc [Member] | Category 3 [Member] | Maximum [Member] | |||||||||||
| Amount of sales limit | $ 1,000,000,000 | ||||||||||
| CoNCERT Pharmaceuticals, Inc [Member] | Category 3 [Member] | Minimum [Member] | |||||||||||
| Amount of sales limit | 500,000,000 | ||||||||||
| CoNCERT Pharmaceuticals, Inc [Member] | Category 4 [Member] | Minimum [Member] | |||||||||||
| Amount of sales limit | $ 1,000,000,000 | ||||||||||
| Promet [Member] | Category 1 [Member] | |||||||||||
| Percentage of sales percentage | 10.00% | 10.00% | |||||||||
| Promet [Member] | Category 2 [Member] | |||||||||||
| Percentage of sales percentage | 50.00% | 50.00% | |||||||||